CL2016001918A1 - Heteroaril amidas como inhibidores de agregación de proteína - Google Patents

Heteroaril amidas como inhibidores de agregación de proteína

Info

Publication number
CL2016001918A1
CL2016001918A1 CL2016001918A CL2016001918A CL2016001918A1 CL 2016001918 A1 CL2016001918 A1 CL 2016001918A1 CL 2016001918 A CL2016001918 A CL 2016001918A CL 2016001918 A CL2016001918 A CL 2016001918A CL 2016001918 A1 CL2016001918 A1 CL 2016001918A1
Authority
CL
Chile
Prior art keywords
protein aggregation
aggregation inhibitors
disease
heteroaryl amides
protein
Prior art date
Application number
CL2016001918A
Other languages
English (en)
Spanish (es)
Inventor
Emily M Stocking
Wolfgang Wrasidlo
Original Assignee
Neuropore Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52484559&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016001918(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neuropore Therapies Inc filed Critical Neuropore Therapies Inc
Publication of CL2016001918A1 publication Critical patent/CL2016001918A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2016001918A 2014-01-29 2016-07-28 Heteroaril amidas como inhibidores de agregación de proteína CL2016001918A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461933246P 2014-01-29 2014-01-29
US201462078895P 2014-11-12 2014-11-12

Publications (1)

Publication Number Publication Date
CL2016001918A1 true CL2016001918A1 (es) 2017-01-13

Family

ID=52484559

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016001918A CL2016001918A1 (es) 2014-01-29 2016-07-28 Heteroaril amidas como inhibidores de agregación de proteína

Country Status (38)

Country Link
US (3) US9738635B2 (OSRAM)
EP (2) EP3099684B8 (OSRAM)
JP (2) JP6619741B2 (OSRAM)
KR (1) KR102383038B1 (OSRAM)
CN (2) CN106132960B (OSRAM)
AP (1) AP2016009347A0 (OSRAM)
AU (1) AU2015211119B2 (OSRAM)
BR (2) BR122018001892B1 (OSRAM)
CA (1) CA2937967C (OSRAM)
CL (1) CL2016001918A1 (OSRAM)
CR (1) CR20160394A (OSRAM)
CY (2) CY1120348T1 (OSRAM)
DK (2) DK3099684T3 (OSRAM)
EA (1) EA032374B1 (OSRAM)
EC (1) ECSP16070327A (OSRAM)
ES (2) ES2808978T3 (OSRAM)
HK (1) HK1231470A1 (OSRAM)
HR (2) HRP20180813T1 (OSRAM)
HU (2) HUE050964T2 (OSRAM)
IL (1) IL246987B (OSRAM)
LT (2) LT3348556T (OSRAM)
ME (1) ME03800B (OSRAM)
MX (1) MX2016009896A (OSRAM)
MY (1) MY187450A (OSRAM)
NZ (1) NZ722487A (OSRAM)
PE (1) PE20161393A1 (OSRAM)
PH (1) PH12016501493B1 (OSRAM)
PL (2) PL3099684T3 (OSRAM)
PT (2) PT3099684T (OSRAM)
RS (2) RS60547B1 (OSRAM)
SA (1) SA516371579B1 (OSRAM)
SG (1) SG11201606108RA (OSRAM)
SI (2) SI3348556T1 (OSRAM)
SM (2) SMT201800318T1 (OSRAM)
TR (1) TR201809440T4 (OSRAM)
UA (1) UA118209C2 (OSRAM)
WO (1) WO2015116663A1 (OSRAM)
ZA (1) ZA201605246B (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ722487A (en) 2014-01-29 2022-04-29 Ucb Biopharma Sprl Heteroaryl amides as inhibitors of protein aggregation
EP3328379B1 (en) * 2015-07-29 2021-07-28 UCB Biopharma SRL Bis-heteroaryl derivatives as modulators of protein aggregation
CN106474121B (zh) * 2016-11-25 2017-10-10 刘淑兰 一种治疗慢性盆腔炎的药物
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
RU2019126170A (ru) * 2017-01-26 2021-02-26 Юсб Байофарма Спрл Бисгетероарильные производные в качестве модуляторов агрегации белков
JP7073385B2 (ja) * 2017-01-26 2022-05-23 ユーシービー バイオファルマ エスアールエル タンパク質凝集のモジュレーターとしての二環式ビス－ヘテロアリール誘導体
EP3573981B1 (en) * 2017-01-26 2022-03-16 UCB Biopharma SRL Alkoxy bis-heteroaryl derivatives as modulators of protein aggregation
EP3634403B1 (en) * 2017-05-12 2025-06-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Phenyl-heterocycle-phenyl derivatives for use in the treatment or prevention of melanoma
CA3108484A1 (en) 2017-08-04 2019-02-07 Anthony Stewart Campbell Inhibitors of microbially induced amyloid
CA3079831A1 (en) * 2017-10-31 2019-05-09 Loma Linda University Methods for treating traumatic brain injury
US11707452B2 (en) 2018-08-20 2023-07-25 Arvinas Operations, Inc. Modulators of alpha-synuclein proteolysis and associated methods of use
EP4458824A4 (en) 2021-12-27 2025-12-24 Shanghai Jingxin Biomedical Co Ltd Fused bicyclic heteroarylamide compound useful as a protein aggregation inhibitor
GB202213796D0 (en) * 2022-09-21 2022-11-02 Wista Lab Ltd Tau aggregation inhibitors
EP4611895A1 (en) * 2022-11-02 2025-09-10 AC Immune SA Novel compounds for the diagnosis of tdp-43 proteinopathies
WO2024184179A1 (en) 2023-03-06 2024-09-12 UCB Biopharma SRL Minzasolmin for use in the treatment of parkinson's disease
WO2024184180A1 (en) 2023-03-06 2024-09-12 UCB Biopharma SRL Minzasolmin for use in the treatment of parkinson's disease
WO2025002040A1 (zh) * 2023-06-25 2025-01-02 上海京新生物医药有限公司 双环杂芳基酰胺化合物的晶型及盐、制备方法和用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1463997A (en) * 1995-12-22 1997-07-17 Acea Pharmaceuticals, Inc. Subtype-selective nmda receptor ligands and the use thereof
EA200500721A1 (ru) * 2002-11-28 2005-12-29 Шеринг Акциенгезельшафт Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств
CN101385722A (zh) * 2003-02-27 2009-03-18 乔安妮·麦克劳林 预防、治疗和诊断蛋白聚集疾病的方法
PL1697371T3 (pl) * 2003-12-19 2007-09-28 Bristol Myers Squibb Co Azabicykliczne heterocykle jako modulatory receptora kanabinoidowego
TW200528455A (en) * 2003-12-19 2005-09-01 Bristol Myers Squibb Co Azabicyclic heterocycles as cannabinoid receptor modulators
KR20070018824A (ko) * 2003-12-19 2007-02-14 브리스톨-마이어스 스큅 컴퍼니 카나비노이드 수용체 조절제인 아자비사이클릭헤테로사이클
EA013678B1 (ru) * 2004-08-26 2010-06-30 Пфайзер Инк. Энантиомерно чистые аминогетероарильные соединения в качестве ингибиторов протеинкиназы
CA2580725A1 (en) * 2004-09-20 2006-03-30 4Sc Ag Novel heterocyclic nf-kb inhibitors
SE0403119D0 (sv) * 2004-12-21 2004-12-21 Astrazeneca Ab Therapeutic agents
US20100168102A9 (en) 2005-07-11 2010-07-01 Devgen Nv Amide Derivatives as Kinase Inhibitors
SG172738A1 (en) * 2005-07-29 2011-07-28 4Sc Ag Novel heterocyclic nf-kb inhibitors
JP2009529555A (ja) * 2006-03-15 2009-08-20 ４エスツェー アクチェンゲゼルシャフト 新規複素環式ＮＦ−κＢ阻害薬
EP2081892A4 (en) * 2006-11-17 2014-03-05 Donald F Weaver COMPOUNDS AND METHOD FOR THE TREATMENT OF PROTEIN DISAPPEARANCE
WO2008157425A2 (en) * 2007-06-14 2008-12-24 The Regents Of The University Of California Compounds for inhibiting protein aggregation, and methods for making and using them
US8598356B2 (en) * 2008-11-25 2013-12-03 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
GB0910003D0 (en) * 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
WO2011048525A1 (en) 2009-10-20 2011-04-28 Pfizer Inc. Novel heteroaryl imidazoles and heteroaryl triazoles as gamma-secretase modulators
JP5922031B2 (ja) 2009-12-16 2016-05-24 ニューロポア セラピーズ，インコーポレイティド 化合物
GB201021103D0 (en) 2010-12-13 2011-01-26 Univ Leuven Kath New compounds for the treatment of neurodegenerative diseases
WO2013134371A1 (en) 2012-03-06 2013-09-12 Neuropore Therapies, Inc. Methods and compounds to be used in the treatment of neurodegenerative diseases
KR20150002713A (ko) 2012-03-28 2015-01-07 뉴로포레 테라피스, 인코포레이티드 단백질 응집 저해제로서의 페닐-우레아 및 페닐-카바메이트 유도체
JP2015522617A (ja) 2012-07-16 2015-08-06 ニューロポア セラピーズ，インコーポレイティド タンパク質凝集の阻害剤としてのジ−およびトリ−ヘテロアリール誘導体
NZ722487A (en) 2014-01-29 2022-04-29 Ucb Biopharma Sprl Heteroaryl amides as inhibitors of protein aggregation
EP3328379B1 (en) 2015-07-29 2021-07-28 UCB Biopharma SRL Bis-heteroaryl derivatives as modulators of protein aggregation
RU2019126170A (ru) 2017-01-26 2021-02-26 Юсб Байофарма Спрл Бисгетероарильные производные в качестве модуляторов агрегации белков
JP7073385B2 (ja) 2017-01-26 2022-05-23 ユーシービー バイオファルマ エスアールエル タンパク質凝集のモジュレーターとしての二環式ビス－ヘテロアリール誘導体

Also Published As

Publication number Publication date
SMT201800318T1 (it) 2018-07-17
SMT202000376T1 (it) 2020-09-10
US9738635B2 (en) 2017-08-22
EP3348556B1 (en) 2020-04-29
PL3099684T3 (pl) 2018-09-28
CY1120348T1 (el) 2019-07-10
EP3099684A1 (en) 2016-12-07
HUE040274T2 (hu) 2019-03-28
HRP20180813T1 (hr) 2018-07-27
HK1231470A1 (zh) 2017-12-22
BR112016017344A2 (pt) 2017-10-03
AU2015211119A1 (en) 2016-08-11
HUE050964T2 (hu) 2021-01-28
US20160207912A1 (en) 2016-07-21
PH12016501493A1 (en) 2017-02-06
BR112016017344B1 (pt) 2023-05-16
NZ722487A (en) 2022-04-29
CN106132960B (zh) 2019-12-17
EP3099684B1 (en) 2018-04-04
EP3099684B8 (en) 2018-07-04
IL246987A0 (en) 2016-09-29
EA201691529A1 (ru) 2017-01-30
CR20160394A (es) 2016-11-01
CN106132960A (zh) 2016-11-16
ES2808978T3 (es) 2021-03-02
AP2016009347A0 (en) 2016-07-31
ES2808978T8 (es) 2021-03-22
SI3099684T1 (en) 2018-08-31
JP6783900B2 (ja) 2020-11-11
UA118209C2 (uk) 2018-12-10
WO2015116663A1 (en) 2015-08-06
DK3348556T3 (da) 2020-08-03
JP2019163321A (ja) 2019-09-26
RS57533B1 (sr) 2018-10-31
IL246987B (en) 2021-12-01
ZA201605246B (en) 2022-05-25
US20180093979A1 (en) 2018-04-05
DK3099684T3 (en) 2018-07-16
SA516371579B1 (ar) 2019-07-16
CA2937967C (en) 2022-07-26
AU2015211119A8 (en) 2016-12-15
WO2015116663A8 (en) 2016-09-15
EA032374B1 (ru) 2019-05-31
US20190308965A1 (en) 2019-10-10
LT3348556T (lt) 2020-08-10
AU2015211119B2 (en) 2019-05-30
PT3348556T (pt) 2020-07-27
TR201809440T4 (tr) 2018-07-23
PL3348556T3 (pl) 2020-11-02
PT3099684T (pt) 2018-10-22
KR102383038B1 (ko) 2022-04-05
EP3348556A1 (en) 2018-07-18
PE20161393A1 (es) 2017-01-08
CN111039939A (zh) 2020-04-21
CN111039939B (zh) 2023-09-19
US11078196B2 (en) 2021-08-03
CY1123374T1 (el) 2021-12-31
ME03800B (me) 2021-04-20
CA2937967A1 (en) 2015-08-06
MY187450A (en) 2021-09-22
JP6619741B2 (ja) 2019-12-11
ECSP16070327A (es) 2018-05-31
HRP20201107T8 (hr) 2020-12-11
JP2017505779A (ja) 2017-02-23
RS60547B1 (sr) 2020-08-31
SG11201606108RA (en) 2016-08-30
LT3099684T (lt) 2018-06-25
BR122018001892B1 (pt) 2023-05-02
MX2016009896A (es) 2017-01-11
KR20160113287A (ko) 2016-09-28
US10358443B2 (en) 2019-07-23
PH12016501493B1 (en) 2017-02-06
HRP20201107T1 (hr) 2020-10-30
SI3348556T1 (sl) 2020-10-30
ES2675301T3 (es) 2018-07-10

Similar Documents

Publication Publication Date Title
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
CL2015000942A1 (es) Compuestos de benceno sustituido.
MX390014B (es) Compuestos de dinucleótidos cíclicos y métodos de uso.
MX378273B (es) Compuestos activos hacia bromodominios.
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
WO2015153959A3 (en) Small molecule inhibitors of mcl-1 and uses thereof
CL2015002767A1 (es) Compuestos terapéuticos y composiciones
CL2015002698A1 (es) Nuevos compuestos y composiciones para la inhibicion de fasn
MY187047A (en) Selective pyy compounds and uses thereof
CL2015002897A1 (es) Inhibidores de bace1
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
MX389178B (es) Formulacion de proporcion fija de insulina glargina/lixisenatida.
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
MX389026B (es) Una composicion farmaceutica y el uso de la misma.
CL2016002879A1 (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
EA201691741A1 (ru) Фармацевтическая композиция
CL2016000884A1 (es) Derivados de piperazina y su uso como medicamento.
CL2015003431A1 (es) Derivados de piridona para el tratamiento de infecciones virales y enfermedades adicionales
CY1119522T1 (el) (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
CO2018011420A2 (es) Formulaciones líquidas de fosfaplatino
CL2017002229A1 (es) Inhibidores de bace1.